Roche is considering seeking accelerated U.S. approval for its Alzheimer’s drug trontinemab, which shows promise in significantly lowering amyloid protein levels linked to cognitive decline. Early Phase 2 data indicates it may clear amyloid more quickly than competitors, with fewer side effects like ARIA. The company plans to expand its trial to 120 participants while adjusting safety criteria after a related incident.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
